NMS Labs Appoints Pierre Cassigneul Chief Executive Officer

WILLOW GROVE, Pa.--(BUSINESS WIRE)-- NMS Labs today announced that it has appointed Pierre Cassigneul as President and Chief Executive Officer, as well as to its Board of Directors. The appointment of Mr. Cassigneul, a highly accomplished entrepreneur and healthcare executive, signals a continued focus on product and service innovation coupled with an unwavering commitment to providing quality solutions in public health and safety. 

Mr. Cassigneul has over 25 years experience leading organizations and high-growth-potential start-ups through the development and launch of innovative tests and high-science clinical diagnostic solutions. His most recent professional experience is in the area of molecular diagnostics as President and CEO of Predictive Biosciences and previously, XDx, Inc. Mr. Cassigneul was born in France where he graduated from Reims Management School. 

Pierre Cassigneul said, "NMS Labs is an unrivalled leader in clinical and forensic toxicology testing, endocrinology excellence and law enforcement solutions with a tremendous array of talent and capabilities. I am delighted to now be at the helm at such an exciting time for the company with its emerging opportunities in novel diagnostics and comprehensive forensic solutions both domestically and internationally." 

Dr. Eric Rieders, Chairman of the Board said, "It is a great pleasure for us to welcome Pierre Cassigneul to NMS Labs. As Chief Executive Officer, he will be responsible for delivering sustainable profitability while continuing the company's tradition of quality and innovation. His deep knowledge of the clinical industry as well as his experience internationally will be pivotal in helping the company pursue its new and ongoing ventures. I am thrilled that this seasoned professional has chosen to join our firm at what I see as an inflection point in our history." 

About NMS Labs: 

NMS Labs is an ISO accredited, international forensic and clinical reference laboratory that is unsurpassed in its scope, accuracy of results, scientific expertise, and innovation. The state-of-the-art facilities include clinical, forensic and research capabilities, dedicated and secure crime laboratories, and are staffed by more than 250 highly trained professionals. NMS Labs is passionate about promoting public health and safety. 

Contact:

NMS Labs

Amanda Shirk, Marketing

215-366-1405 

Suggested Articles

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.